Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells

BACKGROUND: High-dose IL-2 (HDIL2) is approved for the treatment of metastatic melanoma and renal cell carcinoma, but its use is limited in part by toxicity related to the development of vascular leak syndrome (VLS). Therefore, an understanding of the mechanisms that underlie the initiation and prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Won, Zloza, Andrew, Broucek, Joseph, Schenkel, Jason M, Ruby, Carl, Samaha, Georges, Kaufman, Howard L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062649/
https://www.ncbi.nlm.nih.gov/pubmed/24885155
http://dx.doi.org/10.1186/1479-5876-12-113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062649/
https://www.ncbi.nlm.nih.gov/pubmed/24885155
http://dx.doi.org/10.1186/1479-5876-12-113

Ejemplares similares